Inventor · disambiguated record
Johnson Yiu-Nam Lau
Also filed as: LAU JOHNSON · LAU JOHNSON Y · LAU JOHNSON Y N · LAU JOHNSON YIU-LAM
51 granted patents·38 pending applications·438 citations·filing 1999–2024
97Inventor score
Files withATHENEX HK INNOVATIVE LTD9VERSITECH LTD7ATHENEX INC6TAIVEX THERAPEUTICS CORP5NANSHA BIOLOGICS HONG KONG LTD4
Top patents by PatentIndex Score
89 records- 0196US6815542B2Nucleoside compounds and uses thereofRIBAPHARM INC·Filed 2002·Granted Nov 9, 2004·99 cites·6 claims
- 0296US6495677B1Nucleoside compoundsFiled 2000·Granted Dec 17, 2002·138 cites·7 claims
- 0392US7081449B2Pyrido[2,3-d]pyrimidine and pyrimido[4,5-d]pyrimidine nucleosidesVALEANT RES & DEV·Filed 2001·Granted Jul 25, 2006·72 cites·21 claims
- 0491US6831069B2Pyrrolo[2,3-d]pyrimidine nucleoside analogsRIBAPHARM INC·Filed 2001·Granted Dec 14, 2004·51 cites·7 claims
- 0590US10617693B2Methods of treating and/or preventing actinic keratosisATHENEX INC·Filed 2018·Granted Apr 14, 2020·6 cites·25 claims
- 0687US11497750B2Methods of treating and/or preventing actinic keratosisATHENEX INC·Filed 2020·Granted Nov 15, 2022·2 cites·23 claims
- 0785US11739089B2Acetamido-phenyltetrazole derivatives and methods of using the sameATHENEX INC·Filed 2021·Granted Aug 29, 2023·2 cites·23 claims
- 0885US10849893B2Therapeutic combinations of orally administered docetaxel and a P-gp inhibitor for the treatment of cancerATHENEX HK INNOVATIVE LTD·Filed 2019·Granted Dec 1, 2020·2 cites·32 claims
- 0982US11389442B2Therapeutic combinations of orally administered docetaxel and a P-gp inhibitor for the treatment of cancerATHENEX HK INNOVATIVE LTD·Filed 2020·Granted Jul 19, 2022·1 cites·19 claims
- 1081US9409902B2Modulators of HEC1 activity and methods thereforTAIVEX THERAPEUTICS CORP·Filed 2014·Granted Aug 9, 2016·6 cites·16 claims
- 1181US8946268B2Modulators of HEC1 activity and methods thereforLAU JOHNSON·Filed 2011·Granted Feb 3, 2015·15 cites·15 claims
- 1279US10835511B2Oral taxane compositions and methodsATHENEX HK INNOVATIVE LTD·Filed 2016·Granted Nov 17, 2020·3 cites·19 claims
- 1377US8566231B2Method and system for providing buyer bank payable discounting aggregation servicesREID WILLIAM·Filed 2005·Granted Oct 22, 2013·5 cites·30 claims
- 1476US2025115589A1Polymorphisms of HM30181 MesylateHEALTH HOPE PHARMA LTD·Filed 2024·Application pending·0 cites
- 1573US12227494B2Polymorphisms of HM30181 mesylateATHENEX R&D LLC·Filed 2023·Granted Feb 18, 2025·0 cites·3 claims
- 1670US11931417B2Methods of preparing a pegylated human IL-11 compositionNANSHA BIOLOGICS HONG KONG LTD·Filed 2021·Granted Mar 19, 2024·0 cites·8 claims
- 1770US11739079B2Polymorphisms of HM30181 mesylateATHENEX R&D LLC·Filed 2021·Granted Aug 29, 2023·0 cites·2 claims
- 1870US2023046869A1Therapeutic combinations of orally administered docetaxel and a p-gp inhibitor for the treatment of cancerATHENEX HK INNOVATIVE LTD·Filed 2022·Application pending·0 cites
- 1969US7638496B2Nucleoside analogs with carboxamidine modified monocyclic baseVALEANT PHARMACEUTICALS NORTH·Filed 2002·Granted Dec 29, 2009·1 cites·4 claims
- 2067US8962686B2Method and medication for prevention and treatment of ocular hypertension and glaucomaLAM DENNIS SHUN CHIU·Filed 2011·Granted Feb 24, 2015·3 cites·10 claims
- 2166US10946103B2Methods of treatment using a branched amino terminal pegylated Il-11 compositionNANSHA BIOLOGICS HONG KONG LTD·Filed 2019·Granted Mar 16, 2021·0 cites·7 claims
- 2266US10881739B2Interleukin-11 PEGylation reaction intermediate compositionNANSHA BIOLOGICS HONG KONG LTD·Filed 2019·Granted Jan 5, 2021·0 cites·7 claims
- 2366US10588909B2Modulators of HEC1 activity and methods thereforTAIVEX THERAPEUTICS CORP·Filed 2015·Granted Mar 17, 2020·1 cites·12 claims
- 2466US9976183B2Biomarkers for cancers responsive to modulators of HEC1 activityTAIVEX THERAPEUTICS CORP·Filed 2012·Granted May 22, 2018·1 cites·8 claims
- 2566US2023321246A1High-strength oral taxane compositions and methodsATHENEX HK INNOVATIVE LTD·Filed 2023·Application pending·0 cites
- 2666US2023181566A1THERAPEUTIC COMBINATIONS OF ORALLY ADMINISTERED PACLITAXEL AND A P-gp INHIBITOR FOR THE TREATMENT OF ANGIOSARCOMAATHENEX THERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 2765US2023172942A1Methods of treating and/or preventing actinic keratosisATNX SPV LLC·Filed 2022·Application pending·0 cites
- 2864US2025043266A1Compositions and methods for amino acid depletion therapyAVALON POLYTOM HK LTD·Filed 2024·Application pending·0 cites
- 2963US2024307361A1Method for diagnosing and treating irritable bowel syndromeCENTRE FOR CHINESE HERBAL MEDICINE DRUG DEVELOPMENT LTD·Filed 2023·Application pending·0 cites
- 3063US2014235578A1Methods for treating neoplasia and for identifying compositions useful in such therapyUNIV RUTGERS·Filed 2014·Application pending·0 cites
- 3162US2025001030A1Disinfection robots and disinfection methodsLAU JOHNSON YIU NAM·Filed 2024·Application pending·0 cites
- 3262US2024344108A1Galactose rapid quantitative detection system and use thereofAVALON HEPAPOC LTD·Filed 2024·Application pending·0 cites
- 3361US2024390360A1Therapeutic Combinations Of Orally Administered Paclitaxel, A P-gp Inhibitor, And A Checkpoint Inhibitor For The Treatment Of Solid TumorsATHENEX INC·Filed 2022·Application pending·0 cites
- 3460US11963942B2Oral taxane compositions and methodsATHENEX HK INNOVATIVE LTD·Filed 2020·Granted Apr 23, 2024·0 cites·15 claims
- 3559US11357773B2Methods and compositions for enhancing immune response to vaccinationVERSITECH LTD·Filed 2020·Granted Jun 14, 2022·0 cites·13 claims
- 3659US11202921B2Infant phototherapy device, method of use, and kit thereforAVALON PHOTONICS HK LTD·Filed 2019·Granted Dec 21, 2021·1 cites·20 claims
- 3759US2023407559A1Use of siliceous quaternary amines in durable antimicrobial treatment of textile for use in healthcare environmentLAU JOHNSON YUI NAM·Filed 2021·Application pending·0 cites
- 3858US2009176721A1Nucleoside analogs with carboxamidine modified monocyclic baseVALEANT PHARMACEUTICALS NORTH·Filed 2009·Application pending·0 cites
- 3958US2025277735A1Signal detection mechanism and method thereofEMERGING VIRAL DIAGNOSTICS HK LTD·Filed 2023·Application pending·0 cites
- 4058US2019314361A1THERAPEUTIC COMBINATIONS OF ORALLY ADMINISTERED PACLITAXEL AND A P-gp INHIBITOR FOR THE TREATMENT OF ANGIOSARCOMAATHENEX THERAPEUTICS LTD·Filed 2019·Application pending·0 cites
- 4156US11752139B2Therapeutic combinations of orally administered irinotecan and a p-gp inhibitor for the treatment of cancerATHENEX HK INNOVATIVE LTD·Filed 2019·Granted Sep 12, 2023·0 cites·16 claims
- 4256US2024295566A1Method for diagnosing and treating metabolic disordersCENTRE FOR CHINESE HERBAL MEDICINE DRUG DEVELOPMENT LTD·Filed 2023·Application pending·0 cites
- 4355US2023083530A1Disinfection systemAVALON BIOMEDICAL MAN LIMITED·Filed 2020·Application pending·0 cites
- 4455US2011275596A1Methods for treating neoplasia and for identifying compositions useful in such therapyUNIV NEW JERSEY MED·Filed 2010·Application pending·0 cites
- 4554US12213955B2Compositions and methods for broad-spectrum antiviral therapyVERSITECH LTD·Filed 2018·Granted Feb 4, 2025·0 cites·14 claims
- 4654US8606697B2Method and system for providing buyer bank payable discounting servicesREID WILLIAM·Filed 2005·Granted Dec 10, 2013·0 cites·23 claims
- 4754US8571978B2Method and system for providing assurance and financing servicesREID WILLIAM·Filed 2005·Granted Oct 29, 2013·0 cites·30 claims
- 4854US8571977B2Method and system for providing seller bank receivable discounting aggregation servicesREID WILLIAM·Filed 2005·Granted Oct 29, 2013·0 cites·27 claims
- 4954US2019105397A1High-strength oral taxane compositions and methodsATHENEX HK INNOVATIVE LTD·Filed 2018·Application pending·0 cites
- 5053US10335492B2Increasing serum half-life of human IL-11 variants by N-terminal branched PEGylationNANSHA BIOLOGICS HONG KONG LTD·Filed 2016·Granted Jul 2, 2019·0 cites·7 claims
Showing the top 50 of 89 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Johnson Yiu-Nam Lau files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →